NCT04579380 · OUTCOME

Number of Participants With Any Dose Modifications Due to AEs

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations · Source last updated 2026-08-21

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)

What was measured

Dose modification included dose hold, dose reduction, or discontinuation of drugs. Dose reductions or treatment interruption/discontinuation were made at the discretion of the investigator.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2027-12
denom Units Selected: Participants
description: Dose modification included dose hold, dose reduction, or discontinuation of drugs. Dose reductions or treatment interruption/discontinuation were made at the discretion of the investigator.
reporting Status: NOT_POSTED
time Frame: From first dose of the study treatment (Day 1) up to the last dose of study treatment (approximately 52.7 months)
title: Number of Participants With Any Dose Modifications Due to AEs
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice